Logo Image
|Articles|February 23, 2022

Novavax Begins Shipping its COVID-19 Vaccine to European Union Member States

Novavax announces the first doses of Nuvaxovid COVID-19 vaccine have begun shipping to European Union member states.

Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced on Feb. 23, 2022 that the first doses of its Nuvaxovid COVID-19 vaccine have begun shipping to European Union (EU) member states. Nuvaxovid is the first protein-based COVID-19 vaccine authorized for use in Europe.

Nuvaxovid doses are shipping from Novavax’ Netherlands distribution center to EU member states. The first wave of shipments includes several countries, such as Germany, France, and Austria, with shipments to additional EU member states to quickly follow.

The European Commission (EC) granted conditional marketing authorization (CMA) for Nuvaxovid to prevent COVID-19 caused by SARS-Cov-2 in individuals 18 years of age or older. The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended authorization of the vaccine in all 27 EU member states in December 2021.

"Today's announcement paves the way for vaccination with Nuvaxovid to begin in Europe within the coming days. The Novavax COVID-19 vaccine provides a differentiated option to bolster vaccination rates across Europe," said Stanley C. Erck, president and CEO of Novavax, in the press release. "Nuvaxovid has demonstrated efficacy, a reassuring safety and tolerability profile, and is built on a well-understood protein-based vaccine platform used for other vaccines for decades."

Source: Novavax

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more